Search - tctmd.com

Displaying 521 - 540 of 571

Sort: Relevancy | Date

Presentation TCT 2012

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Pro!

Presenter: Gary Ansel

October 22, 2012

Presentation TCT 2012

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Con!

Presenter: Lawrence Garcia

October 22, 2012

Presentation

Drug-eluting Balloon for Treatment of Superficial Femoral Artery In-stent Restenosis

Presenter: E. Stabile

October 04, 2012

Presentation

Prolonged Clopidogrel Use After BMS and DES Placement: The VA Drug-Eluting Stent Study

Presenter: David P. Faxon

June 08, 2012

Presentation

Changes to Polymer Surface of Drug-Eluting Stents During Balloon Expansion

Presenter: 167498|Scott Denardo

May 24, 2012

Presentation EuroPCR 2012

APPOSITION III: Evaluation of the STENTYS self-apposing bare and drug-eluting stent in 1000 STEMI patients in a real-life setting: in-hospital and 30-day outcomes

Presenter: 166648|giovanni amoroso

May 18, 2012

Presentation TCT Mediterranean 2012

Iliofemoral Arterial Disease and Critical Limb Ischemia: Stent and Drug-Eluting Balloon Update

Presenter: Luigi Salemme

May 04, 2012

Presentation TCTAP 2012

Drug-Eluting Stent In Lower Extremity Intervention: Changed Landscape in the Current Practice?

Presenter: Mark W. Burket

April 26, 2012

Presentation TCTAP 2012

Drug-Eluting Balloon or Stent In Femoropopliteal Lesions: How Far Are We?

Presenter: Mark W. Burket

April 25, 2012

Presentation Fellows 2012

Next-Generation Technologies: Bioabsorbable Stents/Polymers, Drug-Eluting Balloons, and More

Presenter: Juan Granada

April 21, 2012

Presentation Fellows 2012

First-Generation Drug-Eluting Stents: The Good, the Bad, and the Ugly

Presenter: Issam Moussa

April 21, 2012

Presentation GI2 2012

10 Reasons Why the Metallic Drug-eluting Stent Should be Replaced by Bioresorbable Scaffold

Presenter: Patrick W. Serruys

April 12, 2012

Presentation GI2 2012

Drug-Eluting Balloon: Clinical Evidence for In-Stent Restenosis

Presenter: Marco V. Wainstein

April 12, 2012

Presentation ACC 2012

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Presenter: Hyo-Soo Kim

March 24, 2012

Presentation ACC 2012

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Presenter: Robert A. Byrne

March 24, 2012

Presentation PCI Outcomes 2012

Controversy 1: Current Drug-Eluting Stents Are Not Only More Effective But Are Safer Than Bare Metal Stents and Should Be Used in more than 90% of (Stented) Patients

Presenter: Gregg W. Stone

March 23, 2012

Presentation

New Drug-eluting Stent Designs: Are Improved Clinical Outcomes Possible?

Presenter: Gregg W. Stone

March 06, 2012

Presentation TCT 2012

Two Years Clinical Outcomes of Diabetic Patients Treated With a New Generation Drug-Eluting Stent.

Presenter: Francesco Saia, William Wijns, Ran Kornowski, Patrick Joly, Fraser Witherow, Enrique Novo Garcia, Dezs? Apr?, Ismail Ates, Ernst G. Vester, Petr Kala, Sinan Dagdelen, Gian Battista Danzi

January 03, 2012

Presentation TCT 2012

The Nine-Month Outcomes of a Polymer-Free Drug-Eluting Stent (YUKON) Compared with Different Polymer Based Drug-Eluting Stents in Real-World Coronary Artery Lesions.

Presenter: Ted S. Trajceski, Lulzim Brovina, Zivko Petrovski, Blerim Zuna, Borce Petrovski

January 03, 2012

Presentation TCT 2012

The impact of paraoxonase-1 activity on the incidence of intra-stent thrombus after drug-eluting stent implantation in the Japanese CYP2C19*2 carriers receiving clopidogrel

Presenter: Ryo Nishio, Junya Shite, Toshiro Shinke, Hiromasa Otake, Masayuki Nakagawa, Ryoji Nagoshi, Amane Kozuki, Takumi Inoue, Hirotoshi Hariki, Tsuyoshi Osue, Yu Taniguchi, Masamichi Iwasaki, Noritoshi Hiranuma, Akihide Konishi, Hiroto Kinutani, Yoko Haraguchi, Tatsuro Ishida, Ken-ichi Hirata

January 03, 2012

Advertisement

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Pro!

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Con!

Drug-eluting Balloon for Treatment of Superficial Femoral Artery In-stent Restenosis

Prolonged Clopidogrel Use After BMS and DES Placement: The VA Drug-Eluting Stent Study

Changes to Polymer Surface of Drug-Eluting Stents During Balloon Expansion

APPOSITION III: Evaluation of the STENTYS self-apposing bare and drug-eluting stent in 1000 STEMI patients in a real-life setting: in-hospital and 30-day outcomes

Iliofemoral Arterial Disease and Critical Limb Ischemia: Stent and Drug-Eluting Balloon Update

Drug-Eluting Stent In Lower Extremity Intervention: Changed Landscape in the Current Practice?

Drug-Eluting Balloon or Stent In Femoropopliteal Lesions: How Far Are We?

Next-Generation Technologies: Bioabsorbable Stents/Polymers, Drug-Eluting Balloons, and More

First-Generation Drug-Eluting Stents: The Good, the Bad, and the Ugly

10 Reasons Why the Metallic Drug-eluting Stent Should be Replaced by Bioresorbable Scaffold

Drug-Eluting Balloon: Clinical Evidence for In-Stent Restenosis

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Biodegradable Polymer Drug-Eluting Stents Versus Durable Polymer Sirolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention

Controversy 1: Current Drug-Eluting Stents Are Not Only More Effective But Are Safer Than Bare Metal Stents and Should Be Used in more than 90% of (Stented) Patients

New Drug-eluting Stent Designs: Are Improved Clinical Outcomes Possible?

Two Years Clinical Outcomes of Diabetic Patients Treated With a New Generation Drug-Eluting Stent.

The Nine-Month Outcomes of a Polymer-Free Drug-Eluting Stent (YUKON) Compared with Different Polymer Based Drug-Eluting Stents in Real-World Coronary Artery Lesions.

The impact of paraoxonase-1 activity on the incidence of intra-stent thrombus after drug-eluting stent implantation in the Japanese CYP2C19*2 carriers receiving clopidogrel

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content